Bergman A, Magnusson A, Moore K, Sundin A, Davies S, Harry D, Ohagen P
Department of Diagnostic Radiology, University Hospital, Uppsala, Sweden.
Acta Radiol. 1998 Sep;39(5):568-71. doi: 10.1080/02841859809172227.
To determine whether the uptake of FP 736-04, a hepatocyte-specific CT contrast agent, is influenced by cirrhotic changes in the liver.
Liver cirrhosis was induced by bile duct ligation (BDL) in Sprague-Dawley rats. Seventy-four animals were divided into three groups comprising: rats with acute BDL; rats with chronic BDL; and normal controls. CT was performed after i.v. infusion of FP 736-04 or saline at a dose of 2 ml/kg b.w., and the mean attenuation in the liver and spleen was measured. The livers from the chronic BDL group were taken for histopathological examination and the extent of the disease was graded according to an arbitrary scale.
There was a significant reduction of the native liver attenuation in both chronic and acute BDL groups as compared with the normal controls. FP 736-04 was taken up by the liver parenchyma with a similar degree of enhancement in all three groups.
确定肝细胞特异性CT造影剂FP 736 - 04的摄取是否受肝脏肝硬化改变的影响。
通过胆管结扎(BDL)诱导Sprague-Dawley大鼠肝硬化。74只动物分为三组,包括:急性BDL大鼠;慢性BDL大鼠;以及正常对照组。静脉注射剂量为2 ml/kg体重的FP 736 - 04或生理盐水后进行CT检查,并测量肝脏和脾脏的平均衰减值。取慢性BDL组的肝脏进行组织病理学检查,并根据任意量表对疾病程度进行分级。
与正常对照组相比,慢性和急性BDL组的肝脏固有衰减均显著降低。三组中肝实质对FP 736 - 04的摄取程度相似。